Clomid is the most popular endogenous Testosterone simulating compound among the anabolic steroid using community. This is due in part because of how long it has been on the market, as well as being the very first fertility drug (for both men and women) that anabolic steroid users first took notice of. Despite the fact that Nolvadex has demonstrated an overall better ability to stimulate Testosterone levels in men, Clomid nevertheless remains a staple compound for hormonal recovery during PCT for most anabolic steroid users. The overwhelming majority of PCT protocols will include Clomid and Nolvadex together for an added effect on HPTA (Hypothalamic Pituitary Testicular Axis) recovery during the post-cycle period, although there are some problems and setbacks related to Clomid’s action that will be covered shortly. Clomid doses in comparison to Nolvadex, for example, will normally need to be in the higher range in order for the compound to do its job in the body, as it is not as powerful as its brother compound Nolvadex, and this will be explained shortly. In terms of Clomid dosages for the purpose of HPTA and endogenous Testosterone restoration, one study has demonstrated that 150mg of Clomid (Clomiphene Citrate) administered daily raised endogenous Testosterone levels of 10 healthy males by approximately 150%, while incidentally, 20mg of Nolvadex (Tamoxifen Citrate) daily raised endogenous Testosterone levels by the same amount. It is very evident here that Clomid is very effective for this purpose, but Nolvadex seems to be a more cost-effective choice seeing as though it is more effective than Clomid when compared mg for mg. INTRODUCTION: Male testosterone deficiency is associated with bad sexual function and quality of life (Qo L). The aim of this study was to determine whether a daily dose of 25 mg clomiphene citrate (CC) is effective in stimulating the endogenous testosterone production pathway and to address the applicability of this medication as a therapeutic option for symptomatic hypogonadism. MATERIALS AND METHODS: This was a prospective study. Men with low sexual desire and testosterone levels (T) below 400 ng/d L were selected to receive CC. Blood samples were obtained to determine baseline measurements of serum T, estradiol, LH, lipid profile and fasting plasma glucose. Each patient was treated with a daily dose of 25 mg CC for at least 3 months. Patients were asked if they experienced any side effects related to the use of CC and if they experienced any improvement in their sexual profile.
You may think of Clomid as primarily a female fertility drug—and it's true that it only has FDA approval for treatment of female infertility. It can help increase sperm count levels and correct hormonal imbalances. But Clomid can be used to treat some cases of male infertility. It can also help you avoid IVF or surgical treatment. In other cases, it may help boost your odds of success after surgery or during IVF. If you're wondering if Clomid can help you, take some time to explore its success rate and potential side effects. This way you can make an educated and empowered decision and have a substantial conversation with your doctor. Your doctor may prescribe Clomid in the following situations. While men being treated for low testosterone usually experience infertility, your doctor may especially consider prescribing Clomid if the low levels are due to hypogonadotropic hypogonadism. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Clomiphene, an oral FDA-approved agent for female infertility has been shown to normalize testosterone levels in men with hypogonadotropic hypogonadism. This study will compare testosterone responses to clomiphene citrate in male veterans with hypothalamic hypogonadism naïve to treatment with responses of similar patients already receiving treatment with injectable or transdermal testosterone. Listing a study does not mean it has been evaluated by the U. This is an open-label, prospective, interventional trial to be conducted in an outpatient specialty care setting. This study aims to explore whether men with low testosterone levels, due to altered brain regulation of male hormone function, who have been previously treated with testosterone, respond as well as men who have not been so treated to clomiphene citrate, an agent commonly used for female infertility that has been shown to improve male hormone secretion in some cases. We will randomize 64 hypogonadal male veterans evenly divided between naive and previous treatment and treat for 8 weeks with clomid, increasing the initial dose of 25 mg to 50 mg/day in those who fail to achieve target testosterone level (450 ng/dl) after the first 3 weeks. Endpoint measurements performed in the Phoenix VA Health Care System (PVAHCS) clinical laboratory will be total testosterone as well as bioavailable testosterone and sex hormone binding globulin. Total testosterone level at 8 weeks of treatment will be reported as the primary endpoint. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. Safety measures (CBC,liver functions, PSA) will be assessed at 8 weeks as well.
We asked Dr. Eric Seaman about Clomid use, particularly if there were any side effects that men who are considering taking Clomid should be. Clomid is typically used as an infertility treatment in women. It’s not approved by the FDA for use in men, but it’s often prescribed off-label for treatment of male infertility.